- 抑制劑
- 研究領(lǐng)域
- PI3K/Akt/mTOR信號(hào)通路
- 表觀遺傳
- 甲基化
- 免疫&炎癥
- 酪氨酸蛋白激酶
- 血管生成
- 凋亡
- 自噬
- 內(nèi)質(zhì)網(wǎng)應(yīng)激&UPR響應(yīng)
- JAK/STAT信號(hào)通路
- MAPK信號(hào)通路
- 細(xì)胞骨架
- 細(xì)胞周期
- TGF-beta/Smad信號(hào)通路
- DNA損傷/DNA修復(fù)
- 化合物庫(kù)
- 抗體
- 生物試劑
- qPCR
- 2x SYBR Green qPCR Master Mix
- 2x SYBR Green qPCR Master Mix(Low ROX)
- 2x SYBR Green qPCR Master Mix(High ROX)
- 蛋白實(shí)驗(yàn)
- Protein A/G免疫沉淀磁珠
- Anti-DYKDDDDK Tag免疫磁珠
- Anti-DYKDDDDK Tag親和凝膠
- Anti-Myc免疫磁珠
- Anti-HA免疫磁珠
- 磁力架
- Poly DYKDDDDK Tag多肽
- 細(xì)胞核與細(xì)胞漿蛋白抽提試劑盒
- 免疫磁珠
- 蛋白酶抑制劑Cocktail
- 蛋白酶抑制劑Cocktail(DMSO儲(chǔ)液)
- 磷酸酶抑制劑Cocktail
- 細(xì)胞實(shí)驗(yàn)
- Cell Counting Kit-8 (CCK-8)
- 動(dòng)物實(shí)驗(yàn)
- 鼠尾直接PCR試劑盒(快速基因型鑒定)
- 小鼠CD3+ T細(xì)胞分選試劑盒
- 小鼠CD4+ T細(xì)胞分選試劑盒
- 小鼠CD8+ T細(xì)胞分選試劑盒
- 新產(chǎn)品
- 聯(lián)系我們
Home
DNA Damage/DNA Repair
DNA/RNA Synthesis inhibitor
-
DNA alkylator chemical
-
Autophagy activator
Oxaliplatin
僅限科研使用
Oxaliplatin
別名: L-OHP,NSC 266046 中文名稱：奧沙利鉑
鉑類藥物不建議使用DMSO溶解，易失活！
Oxaliplatin是一種DNA烷基化藥物可以激活自噬。Oxaliplatin在RT4，TCCSUP，A2780，HT-29，U-373MG，U-87MG，SK-MEL-2，和 HT-144細(xì)胞中通過形成DNA加合物而抑制DNA合成。在溶液中不穩(wěn)定，請(qǐng)現(xiàn)配現(xiàn)用！鉑類藥物不建議用DMSO溶解，易失活！
Oxaliplatin Chemical Structure
CAS: 61825-94-3
產(chǎn)品質(zhì)控
批次：
純度：
99.76%
99.76
Oxaliplatin相關(guān)產(chǎn)品
| 相關(guān)靶點(diǎn) | tRNA synthetase RdRp DNA synthesis helicase ribonucleotide reductase | 點(diǎn)擊展開 |
|---|---|---|
| 相關(guān)產(chǎn)品 | CX-5461 (Pidnarulex) SCR7 Favipiravir (T-705) RK-33 Triapine (3-AP) Carmofur BMH-21 B02 YK-4-279 Bergapten Azaguanine-8 Halofuginone Adenine HCl Tegafur (FT-207) Mizoribine Cyclocytidine HCl Thymidine Nedaplatin APX-3330 Flupirtine maleate Pritelivir (BAY 57-1293) 6-Thio-dG JH-RE-06 TK216 CRT0044876 Adenine Tubercidin Amenamevir Madrasin ML216 PFM01 BC-LI-0186 | 點(diǎn)擊展開 |
| 相關(guān)化合物庫(kù) | FDA藥物庫(kù) 天然產(chǎn)物庫(kù) 凋亡分子化合物庫(kù) DNA損傷/ DNA修復(fù)化合物庫(kù) 細(xì)胞周期化合物庫(kù) | 點(diǎn)擊展開 |
相關(guān)信號(hào)通路圖
細(xì)胞實(shí)驗(yàn)數(shù)據(jù)示例
| 細(xì)胞系 | 實(shí)驗(yàn)類型 | 給藥濃度 | 孵育時(shí)間 | 活性描述 | 文獻(xiàn)信息(PMID) |
|---|---|---|---|---|---|
| SW620 | Function Assay | 10?μg/ml | 24?h | increases LC3-II accumulation and decreases P62 expression | 25749420 |
| SW480 | Function Assay | 10?μg/ml | 24?h | increases LC3-II accumulation and decreases P62 expression | 25749420 |
| SW620 | Function Assay | 10?μg/ml | 24?h | enhances cellular autophagic flux | 25749420 |
| SW480 | Function Assay | 10?μg/ml | 24?h | enhances cellular autophagic flux | 25749420 |
| Panc-1 | Cell Viability Assay | 25/50 μM | 24/48 h | inhibits proliferation of PC cells in a synergistic manner combined with WA | 25444914 |
| MIAPaCa-2 | Cell Viability Assay | 25/50 μM | 24/48 h | inhibits proliferation of PC cells in a synergistic manner combined with WA | 25444914 |
| SW1990 | Cell Viability Assay | 25/50 μM | 24/48 h | inhibits proliferation of PC cells in a synergistic manner combined with WA | 25444914 |
| HPDE | Cell Viability Assay | 25/50 μM | 24/48 h | inhibits proliferation of PC cells in a synergistic manner combined with WA | 25444914 |
| Panc-1 | Apoptosis Assay | 25?μM | 24 h | induces apoptosis in a synergistic manner combined with WA | 25444914 |
| MIAPaCa-2 | Apoptosis Assay | 25?μM | 24 h | induces apoptosis in a synergistic manner combined with WA | 25444914 |
| Panc-1 | Function Assay | 25?μM | 24/48 h | induces cleavage of PARP, caspase-9, caspase-8 and caspase-3? | 25444914 |
| MIAPaCa-2 | Function Assay | 25?μM | 24/48 h | induces cleavage of PARP, caspase-9, caspase-8 and caspase-3? | 25444914 |
| SW480 | Growth Inhibition Assay | 1?μM | 0-72 h | inhibits cell growth in a time dependent manner | 24997451 |
| HT-29 | Growth Inhibition Assay | 1?μM | 0-72 h | inhibits cell growth in a time dependent manner | 24997451 |
| HCT116 | Function Assay | 2/5 μM | 24/48 h | suppresses survivin mRNA expression | 24761411 |
| SW620 | Growth Inhibition Assay | 10-70 mg/L | 24/48/72 h | inhibits cell growth in both time and dose dependent manner | 24646305 |
| Caco2? | Function Assay | 30?μM | 24 h | induces the expression of HO-1, AKR1C, and NQO1 | 24556415 |
| Caco2? | Function Assay | 3/10/30 μM | 16 h | increases the mRNA levels of?AKR1C1, NQO1, HO-1, MRP2,?andMRP3?dose-dependently | 24556415 |
| Caco2 | Function Assay | 30/100?μM | 16?h | activates Nrf2 | 24556415 |
| CT26? | Cell Viability Assay | 4 mM | 48 h? | decreases cell viability to 53.2% | 26137012 |
| CT26? | Function Assay | 4 mM | 48 h? | increases the expression levels of autophagy-related proteins, such as LC3-II, Beclin1 and ATG5 | 26137012 |
| CT26? | Function Assay | 4 mM | 48 h? | induces autophagy | 26137012 |
| SK-OV-3 | Function Assay | 50 μM? | 48 h? | promotes sensitivity of ovarian carcinoma to NK cell-mediated cytolysis | 26138671 |
| OVCAR-5 | Function Assay | 20 μM? | 24h | promotes sensitivity of ovarian carcinoma to NK cell-mediated cytolysis | 26138671 |
| PA-1 | Function Assay | 10 μM? | 24h | promotes sensitivity of ovarian carcinoma to NK cell-mediated cytolysis | 26138671 |
| SK-OV-3 | Function Assay | 50 μM | 96 h | up-regulates the stress ligands for NK cell-activating receptors and TRAIL receptors | 26138671 |
| OVCAR-5 | Function Assay | 30 μM | 48h | up-regulates the stress ligands for NK cell-activating receptors and TRAIL receptors | 26138671 |
| PA-1 | Function Assay | 10 μM? | 48h | up-regulates the stress ligands for NK cell-activating receptors and TRAIL receptors | 26138671 |
| SK-OV-3 | Function Assay | 50 μM | 96 h | triggeres the production of type I IFNs and chemokines | 26138671 |
| OVCAR-5 | Function Assay | 30 μM | 48h | triggeres the production of type I IFNs and chemokines | 26138671 |
| PA-1 | Function Assay | 10 μM? | 24h | triggeres the production of type I IFNs and chemokines | 26138671 |
| SK-OV-3 | Cell Viability Assay | 0-100 μM | 24/48/72 h | inhibits cell viability in both time and dose dependent manner | 26138671 |
| OVCAR-5 | Cell Viability Assay | 0-60 μM | 24/48/72 h | inhibits cell viability in both time and dose dependent manner | 26138671 |
| PA-1 | Cell Viability Assay | 0-20 μM | 24/48 h | inhibits cell viability in both time and dose dependent manner | 26138671 |
| LoVo? | Function Assay | 1/5 μM | 24/48 h | induces transcriptional repression of DUT-N | 26208523 |
| HCT116 p53+/+ | Function Assay | 1/5 μM | 24/48 h | induces transcriptional repression of DUT-N | 26208523 |
| CaES-17 | Cytotoxicity Assay | 0–160?μM | 48?h | IC50=5.5?±?0.2 μM | 26474693 |
| HKESC-2 | Cytotoxicity Assay | 0–160?μM | 48?h | IC50=5.8?±?0.5 μM | 26474693 |
| SW480 | Growth Inhibition Assay | 72 h? | IC50=10.7±2.26 μg/mL | 25360631 | |
| HCT116? | Growth Inhibition Assay | 72 h? | IC50=6.23±0.75 μg/mL | 25360631 | |
| SW480? | Growth Inhibition Assay | 48 h? | IC50=20.8 ug/mL | 24720675 | |
| LoVo | Growth Inhibition Assay | 48 h? | IC50=94.83 μM | 26269759 | |
| HCT116 | Growth Inhibition Assay | 48 h? | IC50=11.86 μM | 26269759 | |
| SW480 | Growth Inhibition Assay | 48 h? | IC50=1.87 μM | 26269759 | |
| HT29 | Growth Inhibition Assay | IC50=63 μM ± 18 | 26004084 | ||
| DLD-1 | Growth Inhibition Assay | IC50=32.2 μM | 26003085 | ||
| HT-29 | Growth Inhibition Assay | IC50=35.6 μM | 26003085 | ||
| SiHa | Growth Inhibition Assay | IC50=0.8 ± 0.1 μM | 25801007 | ||
| S3 | Growth Inhibition Assay | IC50=53.5 ± 1.5 μM | 25801007 | ||
| AGS | Growth Inhibition Assay | IC50=10.6 μM | 25789057 | ||
| MKN-45 | Growth Inhibition Assay | IC50=14.0 μM | 25789057 | ||
| TMK-1 | Growth Inhibition Assay | IC50=22.6 μM | 25789057 | ||
| SCM-1 | Growth Inhibition Assay | IC50=17.5 μM | 25789057 | ||
| HCT-15 | Growth Inhibition Assay | IC50=8.64 μM | 25761479 | ||
| DiFi | Growth Inhibition Assay | IC50=10.95 μM | 25761479 | ||
| DLD-1 | Growth Inhibition Assay | IC50=8.65 μM | 25761479 | ||
| COLO-320DM | Growth Inhibition Assay | IC50=5.38 μM | 25761479 | ||
| SNU-175 | Growth Inhibition Assay | IC50=1.51 μM | 25761479 | ||
| HT-29 | Growth Inhibition Assay | IC50=5.22 μM | 25761479 | ||
| A549 | Growth Inhibition Assay | IC50=5.8 ± 0.6 μM | 25625243 | ||
| A549/CDDP | Growth Inhibition Assay | IC50=18.6 ± 1.2 μM | 25625243 | ||
| COC1 | Growth Inhibition Assay | IC50=46.20?±?3.14 μM | 25307448 | ||
| SGC7901 | Growth Inhibition Assay | IC50=21.73?±?3.08 μM | 25307448 | ||
| A549 | Growth Inhibition Assay | IC50=51.08?±?10.96 μM | 25307448 | ||
| HepG2 | Growth Inhibition Assay | IC50=14.24?±?1.82 μM | 25307448 | ||
| MCF-7 | Growth Inhibition Assay | IC50=14.24?±?1.82 μM | 25307448 | ||
| HCT-116 | Growth Inhibition Assay | IC50=6.24?±?2.97 μM | 25307448 | ||
| HT-29 | Growth Inhibition Assay | IC50>50 μM | 25307448 | ||
| HEK293 | Growth Inhibition Assay | IC50=8.82?±?5.59 μM | 25307448 | ||
| HUVEC | Growth Inhibition Assay | IC50=11.30?±?1.02 μM | 25307448 | ||
| MC38 | Growth Inhibition Assay | IC50=23 μM ± 2 | 26004084 | ||
| SW620 | Growth Inhibition Assay | IC50=3.68 μM | 26023085 | ||
| SW480 | Growth Inhibition Assay | IC50=2.86 μM | 26023085 | ||
| RKO | Growth Inhibition Assay | IC50=1.23 μM | 26023085 | ||
| LoVo | Growth Inhibition Assay | IC50=1.2 μM | 26023085 | ||
| KM12 | Growth Inhibition Assay | IC50=4.37 μM | 26023085 | ||
| HCT116p53- | Growth Inhibition Assay | IC50=1.08 μM | 26023085 | ||
| HCT116 | Growth Inhibition Assay | IC50=1.04 μM | 26023085 | ||
| HCT15 | Growth Inhibition Assay | IC50=1.43 μM | 26023085 | ||
| HT29 | Growth Inhibition Assay | IC50=2.69 μM | 26023085 | ||
| DLD1 | Growth Inhibition Assay | IC50=2.01 μM | 26023085 | ||
| Colo205 | Growth Inhibition Assay | IC50=3.33 μM | 26023085 | ||
| BE | Growth Inhibition Assay | IC50=3.33 μM | 26023085 | ||
| HCT116 | Growth Inhibition Assay | IC50=0.41?±?0.02 μM | 26148596 | ||
| HT29 | Growth Inhibition Assay | IC50=0.88?±?0.2 μM | 26148596 | ||
| SNU-387 | Growth Inhibition Assay | IC50=25?±?2.7 μM | 26160429 | ||
| SNU-475 | Growth Inhibition Assay | IC50＞30 μM | 26160429 | ||
| Hep-G2 | Growth Inhibition Assay | IC50=13.1?±?1.6 μM | 26160429 | ||
| SNU-398 | Growth Inhibition Assay | IC50=6.5?±?1.1 μM | 26160429 | ||
| MDA-MB-231 | Growth Inhibition Assay | IC50=23.1 ± 0.1 μM | 26211591 | ||
| MCF-7 | Growth Inhibition Assay | IC50=15.4 ± 0.3 μM | 26211591 | ||
| SK-BR-3 | Growth Inhibition Assay | IC50=31.0 ± 0.1 μM | 26211591 | ||
| 點(diǎn)擊查看更多細(xì)胞系數(shù)據(jù) | |||||
生物活性
| 產(chǎn)品描述 | Oxaliplatin是一種DNA烷基化藥物可以激活自噬。Oxaliplatin在RT4，TCCSUP，A2780，HT-29，U-373MG，U-87MG，SK-MEL-2，和 HT-144細(xì)胞中通過形成DNA加合物而抑制DNA合成。在溶液中不穩(wěn)定，請(qǐng)現(xiàn)配現(xiàn)用！鉑類藥物不建議用DMSO溶解，易失活！ | |
|---|---|---|
| 特性 | 不建議使用DMSO溶解。[9] | |
| 靶點(diǎn) |
|
| 體外研究(In Vitro) | ||||||
| 體外研究活性 | Oxaliplatin 主要作用機(jī)制是形成DNA交聯(lián)劑而發(fā)揮作用。Oxaliplatin 誘導(dǎo)DNA一級(jí)和二級(jí)結(jié)構(gòu)損傷而導(dǎo)致細(xì)胞凋亡。[1] Oxaliplatin 有效作用于人類黑色素瘤細(xì)胞系C32 和G361，IC50分別為0.98 mM 和0.14 mM。[2] Oxaliplatin有效抑制膀胱癌細(xì)胞系RT4 和 TCCSUP，卵巢癌細(xì)胞系A(chǔ)2780，結(jié)腸癌細(xì)胞系HT-29，膠質(zhì)母細(xì)胞瘤細(xì)胞系U-373MG和U-87MG，和黑色素瘤細(xì)胞株SK-MEL-2和HT-144，IC50分別為11 μM, 15 μM, 0.17 μM, 0.97 μM, 2.95 μM, 17.6 μM, 30.9 μM, 和 7.85 μM。[4] |
|||||
|---|---|---|---|---|---|---|
| 細(xì)胞實(shí)驗(yàn) | 細(xì)胞系 | RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2 和 HT-144 細(xì)胞系 | ||||
| 濃度 | ~100 μM | |||||
| 孵育時(shí)間 | 48 小時(shí) | |||||
| 方法 | 使用 sulforhodamine-B 顯微培養(yǎng)比色測(cè)定法進(jìn)行細(xì)胞毒性研究。實(shí)驗(yàn)第0天細(xì)胞接種在96孔板上，實(shí)驗(yàn)第1天使用Oxaliplatin 處理細(xì)胞，48小時(shí)后，進(jìn)行sulforhodamine-B 檢測(cè)。除了添加Oxaliplatin和最終實(shí)驗(yàn)測(cè)定期間，實(shí)驗(yàn)全程在37°C 下含5% CO2 和 100% 相對(duì)濕度的環(huán)境下進(jìn)行。檢測(cè)到細(xì)胞的初始數(shù)目為每孔2-20 × 103個(gè)細(xì)胞/50 nL。接種和藥物處理期間細(xì)胞數(shù)目如下（a）檢測(cè)時(shí)對(duì)照組細(xì)胞仍處于對(duì)數(shù)期生長(zhǎng);（b）檢測(cè)時(shí)未處理的對(duì)照組細(xì)胞最大吸光度為1.0?1.5；（c）用藥物處理期間細(xì)胞經(jīng)過2倍以上倍增。每種濃度放置8孔。使用Biotek儀器EL309酶標(biāo)儀與IBM PC-兼容型計(jì)算機(jī)在570 和/或 540 nm處測(cè)定。通過計(jì)算機(jī)程序DATALOG將實(shí)驗(yàn)數(shù)據(jù)傳輸且轉(zhuǎn)化為L(zhǎng)OTUS 1-2-3格式，通過比較實(shí)驗(yàn)組和對(duì)照組計(jì)算存活分?jǐn)?shù)。 |
|||||
| 實(shí)驗(yàn)圖片 | 檢測(cè)方法 | 檢測(cè)指標(biāo) | 實(shí)驗(yàn)圖片 | PMID | ||
| Western blot |
VEGFR-1 / NRP-1
p-AKT(Ser473) / AKT / PTEN / p-Src(Tyr416)
| |||||